AbbVie (ABBV) Short-term Investments (2012 - 2025)

AbbVie (ABBV) has reported Short-term Investments for 14 consecutive years, with $28.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Short-term Investments fell 9.68% year-over-year to $28.0 million in Q4 2025; TTM through Dec 2025 was $28.0 million, a 9.68% decrease from a year earlier, with the FY2025 full-year figure at $28.0 million, down 9.68% from the prior year.
• Short-term Investments was $28.0 million for Q4 2025 at AbbVie, down from $42.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $1.5 billion in Q1 2022 and troughed at $1.0 million in Q1 2025.
• A 5-year average of $178.8 million and a median of $28.0 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 6600.0% in 2022 and sank 99.51% in 2023, its largest moves.
• Over 5 years, Short-term Investments stood at $84.0 million in 2021, then slumped by 66.67% to $28.0 million in 2022, then sank by 92.86% to $2.0 million in 2023, then jumped by 1450.0% to $31.0 million in 2024, then declined by 9.68% to $28.0 million in 2025.
• The last three Short-term Investments figures came in at $28.0 million (Q4 2025), $42.0 million (Q3 2025), and $1.0 million (Q1 2025), per Business Quant data.